Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 40 25 versus ZIAC.
Head-to-head clinical analysis: INDERIDE 40 25 versus ZIAC.
INDERIDE-40/25 vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inderide-40/25 is a combination of propranolol (non-cardioselective beta-blocker) and hydrochlorothiazide (thiazide diuretic). Propranolol reduces heart rate, myocardial contractility, and renin secretion via beta-adrenergic receptor blockade. Hydrochlorothiazide inhibits Na+/Cl- cotransporter in distal convoluted tubule, increasing excretion of Na+, Cl-, and water; also reduces peripheral vascular resistance.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
One tablet (40 mg propranolol HCl/25 mg hydrochlorothiazide) orally twice daily; may increase to maximum of 160 mg propranolol/100 mg hydrochlorothiazide per day in divided doses.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Propranolol: 3-6 hours (terminal); clinical context: dosing 2-3 times daily due to short half-life; may accumulate in hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal); clinical context: longer in renal impairment.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Propranolol: extensively metabolized in liver via CYP2D6 and glucuronidation; <1% excreted unchanged in urine. Hydrochlorothiazide: ~70% excreted unchanged in urine via tubular secretion.
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker and Thiazide Diuretic
Beta Blocker + Diuretic